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Abstract
Human interleukins (ILs) are a collection of different biological molecules 
belonging to the group of cytokines, associated with various immune and non-
immune systems and different signaling pathways. ILs contribute to the function 
of different tissues, organs and systems in the human body. They are involved in 
homeostasis, infectious diseases, autoimmune diseases, cancers and even therapeu-
tics. Due to this knowledge, this chapter aims to summarize the importance of the 
IL-1 and IL-2 superfamilies.
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1. Introduction
Human cytokines are consisted of a wide range of proteins (and/or glyco-
proteins) known as immune molecules with different properties that affect both 
immune and non-immune cells. Based on different characteristics, cytokines are 
classified into several groups including interleukins (ILs), interferons (IFNs), 
chemokines and lymphokines [1–4].
In 1979 at the cytokinologists’ meeting of “the Second International 
Lymphokine Workshop” in Switzerland, the term of Interleukin was officially 
proposed for the first time. The proposed term of “Interleukin” was published in a 
letter to the editor by the Journal of Immunology [2, 5–7].
However, this term is not entirely correct, because the ILs are not only limited to 
leukocytes but they also involve other cells other than leukocytes [4]. The majority 
of IL glycoproteins are produced by endothelial cells, monocytes, macrophages 
(MΦs) and T helper (CD4+) lymphocytes [3].
There are several nomenclature systems, which may be applied for the catego-
rization of ILs. However, interleukins are recognized through the capital letters 
IL followed immediately by a dash and a number e.g. IL-17 [3, 5, 8]. One of these 
nomenclature systems was approved by the subcommittee of the nomenclature 
committee of the International Union of Immunological Societies (IUIS) and the 
World Health Organization (WHO). Functional characteristics, structural proper-
ties, amino acid sequences and related homology, types of receptors (among other 
things) may be recognized as important criteria for ILs’ classification [2, 9].
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The authors try to discuss general characteristics, structures, classifications, and 
genomic maps of ILs throughout this chapter.
2. General characteristics and structure of interleukins
ILs as a group of cytokines, which are involved in immune and non-immune cell 
activation, cell adhesion, cell differentiation, cell maturation and cell migration; 
in other words, these proteins act like signaling molecules that induce different 
pathways in the human body. Although ILs encompass a wide range of functions 
and structures, they participate in immunomodulatory activities and also contrib-
ute to pro-inflammatory and anti-inflammatory responses. These processes initiate 
through the attachment of the IL biomolecules to their specific receptors onto the 
cells, which may lead to induction of immune responses. However, the efficacy and 
specificity of these responses is associated with the related receptors, ligands and 
signaling pathways [2, 3, 10, 11].
In addition, IL proteins have pivotal role in cancers. Indeed, these biomolecules 
are produced and secreted by tumor- and immune cells within the tumors. Due to 
these facts, ILs affect the processes of angiogenesis, invasion, growth and immune 
responses related to tumors. Because of the presence of ILs in different cells, tissues 
and organs, they have recognized as invaluable biomarkers in diagnostics and thera-
peutic planning [11, 12].
Up to date, more than 40 ILs have been identified with a wide range of subtypes. 
The structural characteristics of cytokines, including IL proteins, are effective 
criteria for their categorization. In this regard, some IL glycoproteins are divided 
into two groups: type I (class I) and type II (class II) cytokines. Type I cytokines 
bear a general structure comprising four compact α-helices within tensed pack-
ages. The arrangement of the related α-helices involves a four-helix bundle with an 
antiparallel (up-up-down-down) configuration. Type II cytokines obey the same 
structure as described for type I cytokines. However, type II cytokines bear the 
compact packages of six to seven-helix bundles with the configuration of antiparal-
lel arrangement [2, 3, 11, 13–15].
Furthermore, in accordance with the length of bundles made of α-helices, type 
I cytokines are classified into short- and long-chains subclasses. The members of 
long-chain subclass pertaining to type I cytokines encompass bundle peptides with 
more than 165 amino acids, while the members of short-chain subclass belonging 
to type I cytokines possess bundle peptides with less than 165 amino acids [3, 16]. 
Interleukins are classified into the families of IL-1 family, IL-2 family, IL-6 fam-
ily (including ILs 6, 11, 31, cardiotrophin-like cytokine (CLC), cardiotrophin-1 
(CT-1), ciliary neurotrophic factor (CTNF), leukemia inhibitory factor (LIF), and 
oncostatin M (OSM)) [17]; IL-10 family (composed of ILs 10,19, 20, 22, 24, 26) 
[18]; IL-12 superfamily (comprising ILs 12, 23, 27, 35) [19]; and IL-17 family (con-
taining ILs 17 A-D and IL-25 (IL-17E)) [20]. IL-8 belongs to the CXC-chemokines 
and is classified along with them [21].
3. The IL-1 superfamily and the related members
IL-1 superfamily members (IL1-like cytokines) involve functionally quite 
distinct molecules composed of IL-37, as the single member anti-inflammatory 
cytokine, IL-1Ra, IL-36Ra and IL-38 as three well-known receptor block-
ers or antagonists, and IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β, IL-36γ as 
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seven ligands with agonistic functions [2, 3, 22, 23]. The IL-1 is known as the 
pioneer member of the IL-1 superfamily and its receptor was recognized as 
IL-1R. Interestingly, the IL-1R encompasses a molecule of Toll-IL-1 receptor 
(TIR) domain in its structure. The TIR domain – which is identified in both 
structures of IL-1R and toll-like receptor (TLR) glycoproteins – has pivotal roles 
in transduction of internal signals by different stimulators e.g. recognition of 
pathogen/microbe-associated molecular patterns (PAMPs/MAMPs) and danger/
damage-associated molecular patterns (DAMPs) by ectodomain structures of 
TLRs to strengthen the immune responses and inflammation [22, 24–27]. The 
gene clusters of IL-1 superfamily members, excluding ILs 18 and − 33, map within 
chromosome 2 in humans (Table 1) [2, 3, 22].
IL was identified for the first time in 1979. IL-1α and IL-1β proteins (Figure 1) 
have the same biological characteristics but the lowest homology in their sequences. 
Moreover, the nature of IL-1α subunit makes it active with effective biological func-
tions, while the IL-1β is produced as a pro-subunit which the enzyme of caspase-1 
should be activated [3, 12, 22, 29, 34].
The IL-1 superfamily members are produced by different of immune and non-
immune cells such as chondrocytes, dendritic cells (DCs), epithelial- and endothe-
lial cells, keratinocytes, lymphocytes, fibroblasts, MΦs, monocytes, neutrophils 
and smooth muscle cells [2, 35–37].
As presented on Figures 1 and 2 each subunit whether IL-1α or IL-1β, encom-
passes 11 loops and 12 β-strands which appear as a typical configuration of β-trefoil. 
The two ILs 1α and 1β have no specific binding to the IL-1 receptor type I and II, 
respectively; they both can bind both types, but, in case of type I receptor (CD 
121a), with stimulatory action and pathway signaling, and, in case of the type II 
receptor, (decoy receptor that lacks the TIR domain) with inhibitory effect simi-
lar to the IL1Ra binding. The connections between the ligands and receptors are 
supported by the presence of IL-1R accessory co-receptor proteins (IL-1RAcP) to 
prepare proper conformational changes [3, 22].
IL-1 superfamily 
member





IL-1α/IL-1F1 IL-1α/IL1F1 Heterodimer; 
β-trefoil fold
17 kDa 2q14 [2, 22, 28, 29]
IL-1β/IL-1F2 IL-1β/IL-1F2 17 kDa 2q14 [2, 22, 28, 29]
IL-1Ra/IL-1F3 IL-1Ra/IL-1F3 22 kDa 2q14.2 [2, 22, 28, 29]
IL-18/IL-1F4 IL-18/IL-1F4 Homodimer; 
β-trefoil fold
18 kDa 11q22.2-11q22.3 [2, 22, 28, 29]





A/6 β-trefoil fold 35 kDa 2q12-2q14.1 [2, 22, 23, 28]
β/8 B/8 2q14
γ/9 G/9 2q12-2q21
Ra/5 Ra/5 17 kDa 2q14 [2, 22, 28, 30]
IL-37/IL-1F7 IL-37/IL-1F7 β-trefoil fold 17–24 kDa 2q12-2q14.1 [2, 22, 28, 31]
IL-38/IL-1F10 IL-38/IL-1F10 β-trefoil fold 17 kDa 2q14 [2, 22, 28, 32]
Table 1. 
IL-1 superfamily members, related genes, molecular weight and loci.
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The heterodimers of IL-1α and IL-1β activate the inflammatory pathway via 
the employment of MyD88, which may lead to expression of the nuclear factor 
κB (NF-κB) and consequently, to expression of inflammatory products. Thus, the 
Figure 1. 
The IL-1α structure including an α-helix, β-sheets and loops (shown in green color) (PDB ID 5UC6) [33].
Figure 2. 
The IL-1β structure including an α-helix, β-sheets and loops (shown in violet color) (PDB ID 7CHZ) [38].
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IL-1 is known as endogenous pyrogen. The IL-1 functional properties are  
modulated by IL-1Ra. However, the IL-1RAcP binding domain is absent in IL-1Ra. 
Thus, the IL-1 signaling pathway cannot be induced via the IL-1Ra molecule  
[3, 22, 29, 39].
IL-1 is also involved in tumor biology through the processes of angiogenesis, inva-
sion and proliferation. The expression of IL-1 proteins increase within a wide range of 
cancers e.g., melanoma, lung, breast, neck, colon, head among others [11, 40].
IL-18 is another member of IL-1 superfamily, which was identified in 1989 and 
introduced as the triggering factor of interferon-γ (IFN-γ). IL-18, resembling IL-1β 
is produced as an inactive protein and should be activated by the cleavage done via 
caspase-1. IL-18 is the ligand of the double stranded and heterodimeric receptor of 
IL-18R complex. The combined complex of IL-12 and IL-18 may lead to significant 
expression of IFN-γ. The expression of IFN-γ resulted from IL-18 and IL-12  
combination has anti-tumoral effects. The expression of IL-18 increases in  
breast-, hepatocellular-, lung-, esophageal-, ovarian- and renal carcinomas [2, 11, 
22, 29, 34, 41–43]. The immune and non-immune cells (e.g. astrocytes, DCs, kera-
tinocytes, Kupffer-cells, MΦs and osteoblasts) are important resources for IL-18 
expression and secretion [29, 44].
IL-33 as another IL-1 superfamily member contributes to type 2 immunity and 
inflammation. Indeed, the IL-33/ST2 pathway has pivotal roles in activation of type 
2 immunity through triggering of those T helper 2 (Th2) cells which produce sup-
pression of tumorigenicity 2 (ST2) molecules [3, 45–47]. The main resource cells that 
produce IL-33 include keratinocytes, mucosal tissues, fibroblasts, endothelial- and 
epithelial cells [3, 22, 45, 48]. IL-33 binds to the related receptor of IL-1RL1 (or ST2). 
Furthermore, the related co-receptor is IL-1RAcP [45]. The precursor of the alarmin 
cytokine IL-33 is inactivated by caspase-1, while the enzymes of neutrophil elastase 
and serine proteases cathepsin G cleave the IL-33 precursor into active mature 
structures. However, the 30 kDa precursor of IL-33 is functional upon necrotic cell 
death and cell damage [3, 22, 34, 45, 49]. The IL-33 receptor, ST2 mediates activation 
of the MyD88-dependent signaling pathway. The ST2 molecules are produced by 
different innate and adaptive immune cells. The ST2 molecule participates in type 
2 cytokines expressions which are involved in inflammatory and allergic responses 
[3, 22, 29]. IL-33 supports the homeostasis of intestinal microbiota through the 
induction of Immunoglobulin A (IgA) in adaptive immune B cells. In addition, the 
IL-33 receptor of ST2 is capable to inhibit the colorectal cancer via reduction of 
regulatory T cells (Treg) infiltration and enhancement of CD8+ T cells [12, 45, 50].
IL-36 cytokines belong to the subfamily members of IL-1 superfamily. The sub-
family of IL-36 is comprised of three IL-36 receptor (IL-36R) agonists of IL-36α, 
IL-36β, and IL-36γ and an IL-36R antagonist of IL-36Ra. The IL-36α, IL-36β, and 
IL-36γ have 24%, 27% and 20% similar homology with IL-1Ra, respectively and 
30%, 31% and 31% similarity with IL-1β, respectively [23, 51, 52]. The IL-36α, 
IL-36β, and IL-36γ bind to IL-36R through the co-receptor IL-1RAcP. The IL-36α, 
IL-36β, and IL-36γ are expressed as biologically inactive precursors which should be 
activated by proteases of elastase/Cat G, Cat G, proteinase3/elastase/CatG, respec-
tively [23]. The IL-36α, IL-36β, and IL-36γ are recognized as inflammatory cyto-
kines which activate the related signaling pathway via activation of NF-κB, while 
the antagonist of IL-36Ra as the anti-inflammatory cytokine inhibits the inflamma-
tory signaling pathway through inactivation of L-36R [23, 53]. The expression of 
IL-36γ cytokine is observed in cancers of colorectal, esophageal, melanoma, lung 
and neck and squamous cell carcinoma [11, 54].
IL-37, which is the anti-inflammatory member of the IL-1 superfamily was 
identified in 2000. IL-37 cytokines consist of five isoforms including IL-37a (iso-
form 5), IL-37b (isoform 1), IL-37c (isoform 4), IL-37d (isoform 2) (expressed only 
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in the testes and the bone marrow) and IL-37e (isoform 3) (expressed only in the 
testes and the bone marrow). The isoform of IL-37a is the only that is expressed in 
the brain (along with the heart and kidney, like the IL-37b and IL-37c, −and also 
in lymph nodes, bone marrow, placenta, lung-; IL-37a is brain-specific between the 
three), IL-37b is kidney-specific between the three, and, finally, IL-37c is heart-
specific (the only of them expressed in the heart). Moreover, the IL-37b or isoform 
1 is the largest member of the IL-37 isoforms with a length of 218 amino acids. The 
IL-37 isoforms are produced as precursors which should be biologically activated 
by protease enzymes e.g. caspase-1 [55, 56]. The IL-37b has considerable sequence 
similarity with IL-18 and therefore the isoform 2 of IL-37 is capable to bind to the 
α-chain of IL-18 receptor (IL-18Rα) [29, 55]. The IL-37 prevents the progression of 
colon cancer through inhibition of β-catenin [12].
IL-38 is known as bioinformatic cytokine, because it was detected by in silico 
studies. This cytokine was discovered in 2001, and has 41% sequence similarity with 
IL-1Ra, 43% with IL-36Ra and 29% with IL-1β. Interestingly similar to IL-36Ra, 
the IL-38 behaves as an antagonist and binds to IL-36R [3, 22, 57]. The IL-38 gene 
maps to chromosome 2, situated within a gene cluster containing IL-1α-IL-1β-IL-
37-IL-36γ-IL-36α-IL-36β-IL-36Ra-IL-38-IL-1Ra that spans from the centromere to 
the telomere [57]. In accordance with previous studies, IL-38 enhances the pro-
inflammatory immune responses against LPS and inhibits the expression of IL-17 
triggered by Candida albicans and IL-22 [11, 22, 57–59].
4. The IL-2 superfamily and related members
The IL-2 superfamily is known as the γc family of cytokines [2, 3, 29, 60]. The IL-2 
superfamily or γc family of cytokines comprise six members including IL-2, IL-4, 
IL-7, IL-9, IL-15 and IL-21 (Table 2); the members of this superfamily are classified as 
type I cytokines bearing four α-helical bundle. γc (CD132) is the pivotal protein por-
tion of IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 receptors. The first recognized member 
of this family, IL-2 was identified in 1976 as a T-cell growth factor [3, 60–62]. The 
IL-2 superfamily members contribute to a wide range of immune cells’ activities such 
as regulation of B cell development, innate lymphoid cells, natural killer (NK) and T 
cells, differentiation, proliferation and survival of immune cells [60].
The IL-2 cytokine is expressed by a wide range of innate and adaptive immune 
cells, including DCs, NK cells, NK T (NKT) cells, active CD4+ and CD8+ T cells. 
Interestingly, the IL-2 cytokine targets the B immune cells, NK and CD4+ and 
CD8+ T. IL-2Rα (known as Tac antigen or CD25), IL-2Rβ (known as CD122) and 








IL-2 IL-2 monomer 15.5 kDa 4q26-4q27 [2, 29]
IL-4 IL-4 monomer 15 kDa 5q23-5q31 [2, 29]
IL-7 IL-7 monomer 25 kDa 8q12-8q13 [2, 29]
IL-9 IL-9 monomer 14 kDa 5q31-5q35 [2, 29]
IL-15 IL-15 monomer 14–15 kDa 4q31 [2, 29]
IL-21 IL-21 monomer 15 kDa 4q26-4q27 [2, 29]
Table 2. 
IL-2 superfamily members, related genes, molecular weight and loci.
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[3, 29, 60, 61]. The IL-2 cytokine has therapeutic application for some cancers, 
e.g., melanoma and renal carcinoma. IL-2 alone or together with related vaccines 
and/or cytokines can be considered as therapeutic options [11, 63].
IL-4, another member of the IL-2 superfamily, is secreted by activated baso-
phils, eosinophils, mast cells, NKT cells, T helper 2 (Th2) cells and γδ T cells [29, 
64]. It participates in the differentiation of Th2 and Th9, mediates allergic conditions, 
triggers expression of IgE in B cells, and protects the human body from infectious 
diseases caused by extracellular parasites and helminths. However, it was shown 
that rather than IL-4, the ILs of 1, 2, 25, and 33 enhance the process of Th9 differ-
entiation [60, 65]. IL-4 and IL-13 – with 25% sequence similarity – cooperate with 
each other in some functional activities [3, 29, 60, 64].
IL-4 has 2 groups of receptors: type I (composed of IL-4Rα or CD124 and the γc 
or CD132) and type II (involves IL-4Rα and IL-13Rα1). The type I IL-4R is able to 
bind only to IL-4 while the type II IL-4R is capable to bind to the both of IL-4 and 
IL-13 [29, 66]. High levels of IL-4Rs are detected in tumors. The IL-4 participates 
in tumorigenesis through prevention of Th1 activation and activation of Th2. The 
expression of IL-4 increases in different types of cancers including urinary bladder, 
breast, colon, lung ovary, pancreas and the prostate [11, 67].
IL-7 is a critical cytokine in B- and T-lymphocyte development and maturation. 
The main expression resources of IL-7 are immune and non-immune cells, such as B 
cells, DCs, epithelial cells, keratinocytes, MΦs and monocytes. IL-7 is the ligand of 
the complex structured IL-7R which is composed of IL-7Rα or CD127 and the γc or 
CD132 [29, 66]. IL-7 is significantly involved in homeostatic regulation of the both 
groups of immature and mature T cell types [2, 60]. In addition, IL-7 triggers the 
anti-tumoral immune responses and prevents the growth of tumors [11].
IL-9 is expressed by the immune cells of eosinophils, mast cells and T cells of Th2 
and Th9. IL-9 triggers the expression of IgE by the adaptive B immune cells and the 
secretion of mucosal production and chemokines in the bronchi. IL-9 is involved in 
helminth infectious diseases, allergies and asthma. The IL-9R is composed of two 
subunits of IL-9Rα and the γc or CD132 [3, 29]. Moreover, the IL-9 acts as a double-
edged sword. In melanoma, IL-9 acts as tumor inhibitor while in acute leukemia, it 
acts as a tumorigenetic cytokine [11].
IL-15 is expressed by a wide range of immune and non-immune cells consist-
ing CD4+ T cells (functional), monocytes, keratinocytes and skeletal muscle 
cells. IL-15 and IL-2 have significant similarities in their structures. The IL-15R 
involves three subunits of IL-15Rα, IL-2Rβ and the γc or CD132. IL-15 participates 
in proliferation of NK cells and the homeostasis of memory CD8+ T cells [3, 29, 
60]. Additionally, IL-15 has anti-tumoral effects [11]. IL-15, unlike IL-2, does not 
stimulate LTreg, that can be useful in cancer therapy. Treg stimulation is one of the 
negative sides of IL-2 that IL-15 does not share [68–70].
IL-21 is expressed by immune cells such as NKT, T and mainly by Th17 and T 
follicular helper (Tfh) [29, 60]. Similarly to IL-4, IL-21 enhances the expression of 
IgG1; on the other hand, conversely from IL-4, IL-21 prevents the expression of IgE 
[60, 71]. The IL-21 receptor is composed of two subunits of IL-21R and the γc or 
CD132. IL-21 has anti-tumoral effects on some groups of cancers which may lead 
to recuperate melanoma and renal carcinoma; while the IL-21 is tumorigenic in 
colorectal cancer [3, 11].
5. Conclusion
Cytokines involve a wide range of molecules with different structural character-
istics, functional properties and biological activities. Identification and recognition 
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of these characteristics help us to understand their classification and categorization. 
Each group of these biomolecules has its massive importance and huge applica-
tion prospects. Indeed, ILs have pivotal roles in different parts of the human body, 
particularly associated with the innate and adaptive immune system. A complete 
understanding of ILs characteristics and properties will improve the successful 
outcomes against infectious and autoimmune diseases, as well as cancers.
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